Problems We Are Solving
The genomics revolution has created a data tsunami. We have developed a novel approach for managing Immuno-Oncology clinical trials and translational research. Our software suite is solving the following problems.
- Difficulties in correlating clinical data and exploratory data
- Problems related to understanding the MOA for new clinical trial candidates
- Issues related to proper monitoring of the subject’s health during a clinical trial
- Roadblocks in the analysis of diverse multi-omics and clinical datasets that prevent investigators in gathering predictive insights
“Our vision is to provide an innovative platform to help you find the right medicine for the right patients at the right time, regionally and globally. We are looking for a few good men and women across different disciplines who have passion for this mission and take great pride in building game-changing products and solutions for cancer patients around the world and who believe in our principles”
“Our mission is to be the technology catalyst to enable our collaborators/customers to find a cure for cancer, COVID-19 and rare orphan diseases. It is our firm belief that the intersection of innovations in technology, science and business is the only way to fight deadly disease.”
Board of Directors and Advisors
Highly skilled employees in multidisciplinary teams
Offices in USA and India, Partnered with Avantor in Europe
Global Standards in Data Protection
Biospecimen workflow for efficient trial operations
Actionable biological insights
Overcome insights missed by traditional bioinformatics tools.
Leveraging AI, ML and NLP
View our 2019 Company brochure for an easy to read guide on our offered product.
Accelarating biomarker discovery in I/O using AI
Collaborative case study for Academic centres
AI-powered Life Science Analytics Cloud (LSAC) technology platform will empower researchers around the world to dynamically visualize, analyze, and interrogate data across all available programs. LSAC seamlessly integrates, curates, and animates clinical trial data, delivering more actionable insights for faster decision making. Additionally, Saama has already leveraged LSAC’s deep learning capabilities to enable queries of the COVID-19 Open Research Dataset (CORD-19), a publicly available database that contains more than 45,000 scholarly articles about COVID-19 and is intended to help the medical community keep up with the latest research and find the most accurate answers to questions related to the virus and its impact.
Has built a COVID-19 patient symptom survey with electronic health record (EHR) and device integration. Andaman7 is helping patients understand their COVID-19 risk through easy symptom tracking and information. The platform is HIPAA, GDPR, and 21CFRPart11 compliant, and is and available in 22 languages. Andaman7 enables proper privacy controls by patient via recurring consent, and offers the ability to collect patient reported, device and electronic medical record (EMR) data. Their advanced technology delivers information and guidance to patients, and provides access to over 10,000 clinics and hospital EMRs in the U.S.
Operates a global patient data network platform, Patient Network Explorer, which currently has near-real-time access to the EHR-based data of more than 27 million patients. The platform enables flexible queries of demographic data, diagnoses, medications and procedures, and laboratory results, and includes event-based and temporal constraint capabilities.
Clinerion supports research and real-world evidence (RWE) queries for COVID-19 cases, epidemiology, and health economics and outcomes research. Clinerion can track and analyze complex combinations of patient data, longitudinally, to understand patient treatment diagnostics, treatment modalities, co-morbidities and developing cohort and outcome models by country and health care institution. Clinerion works with its partners and hospital networks to support the community, enable patient outreach and facilitate longitudinal epidemiological studies.
(In partnership with Chrysalis Biomed Advisors) is a strategy consulting firm with focus on digital transformation of life sciences companies spanning large global corporations to startups, including pharmaceutical/biotechs, medtech, diagnostics, health information and IT player and healthcare providers.
Founded in 2005 and backed by Artiman Ventures and Sequoia Capital, Cellworks has built the world’s strongest trans-disciplinary team of molecular biologists, cellular pathway modelers, semiconductor engineers, and internet software architects working towards a common goal of fighting disease to improve the lives of patients. Cellworks’ areas of therapeutic focus are oncology, immunology, dermatology and infectious diseases. Cellworks’ mission is to serve patients through advances in precision medicine that significantly improve treatment success.
Strand Life Sciences: Strand Life Sciences is a clinical research and diagnostics company that combines a long track record in bioinformatics with cutting-edge laboratory assays and a vast hospital partner network to drive newer generations of patient care. Strand’s customers include global instrument, diagnostic and pharmaceutical companies. Strand is also a pioneer of genomic testing in India. Strand’s diagnostics menu makes it India’s leading integrated specialized diagnostics company, covering oncology, genetics, fertility, women’s health, infectious diseases and general wellness.
The American Association for Cancer Research (AACR) is the world’s oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer. Founded in 1907 by 11 physicians and scientists, the organization now has more than 34,000 members in over 90 countries.
The American Society of Clinical Oncology (ASCO) is a professional organization
representing physicians of all oncology sub-specialties who care for people with cancer.
Founded in 1964 by Drs. Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, ASCO has nearly 45,000 members worldwide.
The Society for Immunotherapy of Cancer (SITC), previously known as The International Society for Biological Therapy of Cancer (iSBTc) is a professional society of influential scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.